What are considerations for PCSK9 inhibitors?

What are considerations for PCSK9 inhibitors?

• A. For patients not meeting LDL-C goals; side effects include respiratory infections
• B. They are always first-line therapy for high LDL
• C. They do not interact with statins
• D. They cause frequent severe hypoglycemia

Answer: (A)

PCSK9 inhibitors are used as an add-on therapy for patients who do not reach LDL-C goals despite maximally tolerated statin therapy, and they can be used in familial hypercholesterolemia. They lower LDL-C by about 50-60% and are given as subcutaneous injections every 2 to 4 weeks. This makes them a second-line option after statins (often with ezetimibe) rather than first-line therapy. Known adverse effects include respiratory infections and injection-site reactions, not frequent severe hypoglycemia. They also do not have meaningful drug interactions with statins.

PCSK9 inhibitors are used as an add-on therapy for patients who do not reach LDL-C goals despite maximally tolerated statin therapy, and they can be used in familial hypercholesterolemia. They lower LDL-C by about 50-60% and are given as subcutaneous injections every 2 to 4 weeks. This makes them a second-line option after statins (often with ezetimibe) rather than first-line therapy. Known adverse effects include respiratory infections and injection-site reactions, not frequent severe hypoglycemia. They also do not have meaningful drug interactions with statins.